ResMed reported first-quarter results for fiscal 2027 that demonstrate resilience in its core sleep and breathing health business amid a strategic portfolio realignment. Revenue reached $1.4 billion, representing 6 percent growth, or 7 percent on a core constant currency basis after excluding the impact of the recently divested MatrixCare business and currency headwinds. The stronger constant currency result suggests underlying demand remains solid across the company’s primary markets, with both Americas and Rest of World sleep and breathing health segments growing 7 and 8 percent respectively on a comparable basis.
Earnings performance strengthened more sharply than revenue, with non-GAAP diluted earnings per share rising 14 percent to $2.91, while GAAP diluted EPS surged 23 percent to $2.92. This outpaced revenue growth due to margin expansion and improved operational leverage. Non-GAAP gross margin expanded 50 basis points year over year to 62.5 percent, driven by what management attributed to productivity pipeline execution. The earnings beat suggests ResMed is successfully managing cost structures while maintaining investment in innovation and supporting long-term growth initiatives.
Cash generation remained robust, with operating cash flow of $422 million and free cash flow of $374 million during the quarter. Management deployed this capital efficiently, returning $1.0 billion to shareholders through dividends and share repurchases despite completing the MatrixCare divestiture. This capital allocation stance signals management confidence in the business trajectory and shows a commitment to shareholders. The company declared a quarterly dividend of $0.66 per share, payable in December 2026 to CDI holders on the ASX.
ResMed’s strategic execution extended beyond the financial results. The company closed its MatrixCare divestiture, which had weighed on margins, and launched the AirTouch F40, the latest addition to its fabric CPAP mask portfolio targeting the substantial sleep apnea treatment market. A partnership with Eight Sleep to integrate sleep insights technology, combined with an endorsement deal involving NASCAR driver Tyler Reddick following his sleep apnea diagnosis, highlights efforts to expand brand visibility and patient engagement within the treatment ecosystem.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARManagement maintained fiscal 2027 guidance for core constant currency revenue growth of 5 to 7 percent and non-GAAP diluted earnings per share of $12.00 to $12.25. The unchanged guidance suggests confidence in the trajectory, though it also implies management anticipates neither significant upside nor meaningful headwinds for the remainder of the year. The key question for investors centers on whether ResMed can sustain margin expansion as it navigates ongoing supply chain dynamics and competitive pressures in the sleep market. Monitoring quarterly updates for sustained pricing power, mask penetration rates, and adoption pace for the AirTouch F40 will provide visibility into the sustainability of the current trajectory. This announcement is price sensitive and classified as material by the ASX.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR